Clinical News

'FIT for symptomatic patients' workshop - NHSE in partnership with the BSG and ACPGBI

Tuesday, 04 April 2017 09:20

NHSE in partnership with BSG and ACPGBI ran a workshop on the 8th March, with clinicians from across the colorectal pathway, to scope activity and opinions on the potential use of FIT in symptomatic patients. Discussions focused on: what data collection was ongoing already, what the gaps were in our knowledge of FIT, and how clinicians could work collaboratively to fill the gaps in a timely manner. If you would like to find out more please see the summary of the meeting on the website, or contact Sophie Lumley at NHS England This e-mail address is being protected from spambots. You need JavaScript enabled to view it . We are interested to hear about other projects that are either ongoing (as research or service evaluation) or currently in the planning stages, or hear from areas interested in collecting data on FIT in symptomatic patients.

Simethicone Residue in Endoscopes

Tuesday, 28 March 2017 07:44

March 2017

Dr Helen Griffiths, Nurse Consultant & Decontamination Advisor British Society of Gastroenterology

A publication in 2016 in the American Journal of Infection control (Ofstead et al) outlined a potential risk following the identification of residual simethicone in endoscopes following the decontamination process in the United States.

At that time expert opinion in the UK concluded that the decontamination process was not well described and that bacteria found on processed scopes were suggestive of operator contamination and not compromised decontamination. Whilst not seen as a basis for modifying the use of simethicone at that time it has continued to be monitored.

Recently there has been an issue identified in the Republic of Ireland when a colonoscope was sent to Olympus for repair. Preliminary investigation showed what appeared to be signs of Simethicone residue ( Hypromellose, an ingredient of Infacol) in the auxiliary water channel of that colonoscope and subsequently a further two colonoscopes. At this time investigation is ongoing but evidence suggests that scopes were reprocessed in accordance with manufacturers instructions including use of MH-946 injection tube (octopus device).

Simethicone was administered via the flushing pump at a dilution of 25mls (40mgs/ml) in 2 litres of water.

There has been no evidence of resultant infection but until further investigation and testing on compatibility and following discussion with the Decontamination Professional Expert Communication Forum (DPECF) it is advised that Simethicone is administered either orally or via the biopsy port of endoscopes and NOT via either the water bottle or flushing pump devices. This will ensure that manual brushing of relevant channels can take place post procedure. The strength of the dilutent should also be kept to a minimum to achieve the desired effect.

Research - Role of primary care in PBC management: clinician perspectives needed

Thursday, 09 March 2017 11:36

The University of Birmingham and NIHR Birmingham Liver BRU in conjunction with UK-PBC are conducting research into perspectives of patients, GPs and specialists around PBC care and potential future changes including an increased role for primary care. We are looking for gastroenterologists and hepatologists in the West Midlands area to take part in qualitative interviews around the role of stratification. Please see advert below for further details or contact the study team led by Gideon Hirschfield for more details.

IBD Registry: March Headlines

Wednesday, 01 March 2017 10:25

IBD Registry 2017 Roadshow Dates Announced

  • MON 15th MAY EXETER
  • THURS 18th MAY CARDIFF
  • FRI 19th MAY SHEFFIELD
  • TUES 23rd MAY DARLINGTON
  • FRI 2nd JUNE LONDON
  • FRI 9th JUNE BIRMINGHAM
  • AUTUMN 2017 GLASGOW

A series of half-day meetings to support clinical teams as they join the IBD Registry. The sessions provide protected time for teams to learn about the Biologics Audit and QI programme using the IBD Registry, and to develop local plans for Registry adoption. Each meeting will be tailored to local needs and aim to provide information, support and hands-on guidance. Experts from the Registry will be on hand to answer questions, and interactive workshops will provide practical support for teams to work together to develop your own plans. Free to attend due to generous industry sponsorship. Register at http://ibdrroadshow2017.eventreference.com/

Registry Participation

Participation continues to grow, with 91 sites now set up to enter data into the IBD Registry, and over 24,600 patient records submitted. If you have not yet registered to participate in the IBD Registry, would like help uploading your data, or have any other registry related queries please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Quarterly Data Submission

The next quarterly data submission will be at the end of March. If you need any help at all in preparing for this, please contact Data Manager Mark Allan by emailing This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Trusts in England – 40% discount on audit subscriptions by 15th March

We've had an encouraging response to the request for subscriptions from Trusts in England to help the BSG maintain the Biologics Audit now that NHS England funding has been withdrawn.

At £2,500 per annum, the subscription is significantly less than the cost of one patient on biologics treatment for a year. Subscribers will receive benchmarked quarterly reports on the Biologics Audit KPIs focusing on quality improvement topics recommended in the last RCP Biologics Report. Later in the year, it is our intention to include reporting of HES data in relation to the Biologics data.

The BSG has offered to reduce the cost in the first year by 40% if a Trust provides a purchase order by 15th March 2017. We have written to the Chief Executives of all Trusts in England explaining the new arrangements for the Biologics Audit, putting the subscription cost in the context of overall expenditure on biologics for IBD, and reminding them that participation in the Audit is part of the NHS England Quality Accounts requirement.

Some teams have contacted us about submitting data to the IBD Registry if their Trust decides not to subscribe to the Audit. At present, you will still be able to submit data, but the Registry will not be able to provide the Trust with the benchmarked Biologics Audit reports. A copy of the letter to CEOs is available on request to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

DID YOU KNOW?

  • Teams can participate in the IBD Registry using their own choice of data entry systems to suit local needs (including some existing local systems)
  • Being part of the IBD Registry will give teams:
    • Robust local data to manage their biologics patients and IBD service more effectively, efficiently and safely
    • Evidence to benchmark the quality of their service as part of a national audit of the safety and appropriate use of biologics

With our thanks for your continued contribution to the IBD Registry,

Dr Stuart Bloom, IBD Registry Chair & Dr Fraser Cummings, IBD Registry Clinical Lead

DATES FOR YOUR DIARY:

  • MON 15th MAY EXETER ROADSHOW
  • THURS 18th MAY CARDIFF ROADSHOW
  • FRI 19th MAY SHEFFIELD ROADSHOW
  • TUES 23rd or WED 24th MAY DARLINGTON ROADSHOW
  • FRI 2nd JUNE LONDON ROADSHOW
  • FRI 9th JUNE BIRMINGHAM ROADSHOW
  • WED 21 JUNE: IBD REGISTRY SYMPOSIUM AT BSG ANNUAL MEETING, MANCHESTER
  • AUTUMN: GLASGOW ROADSHOW
  • DECEMBER : Publication of the IBD Registry initial report

Page 2 of 13